| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,520,623 | 13 | 100 |
| Quartel Adrian W | Chief Medical Officer | 0 | $0 | 1 | $40,036 | $-40,036 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller | 0 | $0 | 2 | $42,990 | $-42,990 |
| Schafer Joshua | CCO | 0 | $0 | 2 | $126,300 | $-126,300 |
| Watton Corey Michael | director | 0 | $0 | 1 | $138,377 | $-138,377 |
| Thompson Rahsaan | Chief Legal & Compliance | 0 | $0 | 4 | $969,360 | $-969,360 |
| McFarlane Neil F. | President and CEO | 0 | $0 | 3 | $1.2M | $-1.2M |
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need …
Over the last 12 months, insiders at Zevra Therapeutics, Inc. have bought $0 and sold $2.52M worth of Zevra Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Zevra Therapeutics, Inc. have bought $227,271 and sold $1.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $157,800 was made by Shih Alvin (director) on 2025‑09‑12.
| 2026-10-12 | Sale | McFarlane Neil F. | President and CEO | 20,000 0.0336% | $11.25 | $224,948 | -9.32% | |
| 2026-08-14 | Sale | Thompson Rahsaan | Chief Legal & Compliance | 42,666 0.0709% | $11.13 | $474,774 | +0.09% | |
| 2026-08-10 | Sale | Watton Corey Michael | director | 12,300 0.0204% | $11.25 | $138,377 | -1.31% | |
| 2026-06-22 | Sale | Thompson Rahsaan | Chief Legal & Compliance | 34,557 0.0586% | $12.68 | $438,304 | -8.54% | |
| 2026-05-11 | Sale | Thompson Rahsaan | Chief Legal & Compliance | 1,794 0.0032% | $11.30 | $20,272 | +6.90% | |
| 2026-02-09 | Sale | McFarlane Neil F. | President and CEO | 14,625 0.0259% | $8.56 | $125,186 | +25.20% | |
| 2026-02-03 | Sale | Schafer Joshua | CCO | 10,500 0.0187% | $9.19 | $96,500 | +16.48% | |
| 2026-02-03 | Sale | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | 3,000 0.0053% | $9.18 | $27,548 | +16.48% | |
| 2026-02-02 | Sale | McFarlane Neil F. | President and CEO | 91,000 0.162% | $9.38 | $853,425 | +13.68% | |
| 2026-01-30 | Sale | Thompson Rahsaan | Chief Legal & Compliance | 4,080 0.0071% | $8.83 | $36,010 | +17.89% | |
| 2026-01-30 | Sale | Schafer Joshua | CCO | 3,375 0.0059% | $8.83 | $29,800 | +17.89% | |
| 2026-01-30 | Sale | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | 1,750 0.003% | $8.82 | $15,442 | +17.89% | |
| 2026-01-30 | Sale | Quartel Adrian W | Chief Medical Officer | 4,533 0.0079% | $8.83 | $40,036 | +17.89% | |
| 2025-10-10 | Sale | McFarlane Neil F. | President and CEO | 19,500 0.0341% | $10.82 | $210,908 | -7.77% | |
| 2025-09-12 | Shih Alvin | director | 20,000 0.0363% | $7.89 | $157,800 | +26.45% | ||
| 2025-09-12 | FAVORITO TAMARA A | director | 3,175 0.0057% | $7.79 | $24,718 | +26.45% | ||
| 2025-08-19 | Bode John B | director | 5,000 0.0091% | $9.16 | $45,825 | +5.99% | ||
| 2025-06-26 | Sale | Thompson Rahsaan | Chief Legal & Compliance | 24,000 0.0436% | $9.21 | $221,004 | +1.62% | |
| 2025-03-28 | Watton Corey Michael | director | 300 0.0006% | $7.84 | $2,352 | +14.08% | ||
| 2025-03-19 | Bode John B | director | 10,000 0.0185% | $7.96 | $79,624 | +12.33% |
| Watton Corey Michael | director | 1800 0.003% | $18,468.00 | 2 | 1 | +9.06% |
| Clifton R. LaDuane | CFO & Treasurer | 51361 0.0865% | $526,963.86 | 1 | 1 | +21.7% |
| Bode John B | director | 45000 0.0758% | $461,700.00 | 3 | 0 | +18.41% |
| Shih Alvin | director | 20000 0.0337% | $205,200.00 | 1 | 0 | +26.45% |
| Anderson Thomas | director | 20000 0.0337% | $205,200.00 | 1 | 0 | +22.55% |
| FAVORITO TAMARA A | director | 3894 0.0066% | $39,952.44 | 1 | 0 | +26.45% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
$1,344,238 | 38 | 23.07% | $639.18M |
| Increased Positions | 82 | +42.49% | 6M | +14.71% |
| Decreased Positions | 85 | -44.04% | 8M | -19.37% |
| New Positions | 23 | New | 912,762 | New |
| Sold Out Positions | 33 | Sold Out | 3M | Sold Out |
| Total Postitions | 190 | -1.55% | 38M | -4.66% |
| Blackrock, Inc. | $33,670.00 | 7.21% | 4.04M | -44,390 | -1.09% | 2025-09-30 |
| Woodline Partners Lp | $28,991.00 | 6.21% | 3.48M | -1M | -24.69% | 2025-09-30 |
| Vanguard Group Inc | $25,715.00 | 5.51% | 3.08M | +130,676 | +4.43% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $18,557.00 | 3.97% | 2.23M | -2M | -46.62% | 2025-09-30 |
| Nantahala Capital Management, Llc | $16,446.00 | 3.52% | 1.97M | +500,000 | +33.97% | 2025-09-30 |
| Fmr Llc | $13,632.00 | 2.92% | 1.63M | -654,672 | -28.6% | 2025-09-30 |
| State Street Corp | $11,904.00 | 2.55% | 1.43M | +185,633 | +14.95% | 2025-09-30 |
| Geode Capital Management, Llc | $10,845.00 | 2.32% | 1.3M | +57,954 | +4.67% | 2025-09-30 |
| Aigh Capital Management Llc | $10,274.00 | 2.2% | 1.23M | +313,039 | +34.07% | 2025-09-30 |
| Susquehanna International Group, Llp | $10,054.00 | 2.15% | 1.21M | +1M | +646.48% | 2025-09-30 |